Ticker

Vanguard S&P Small-Cap 600 Value Index Fund ETF (VIOV) has recently outperformed peer small-cap ETFs and is rated a cautious buy. VIOV's built-in profitability screen filters out loss-making companies, enhancing quality and supporting outperformance versus the Russell 2000. The fund is well positioned in financials and healthcare, sectors expected to benefit from macro tailwinds and potential rate cuts in 2026.

Aspiriant LLC cut its stake in Vanguard S&P Small-Cap 600 Value ETF (NYSEARCA:VIOV) by 6.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 311,630 shares of the company's stock after selling 21,664 shares during the period. Vanguard S&P Small-Cap

Cambridge Financial Group LLC trimmed its holdings in shares of Vanguard S&P Small-Cap 600 Value ETF (NYSEARCA:VIOV) by 25.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 39,975 shares of the company's stock after selling 13,770 shares during the period. Vanguard S&P

Launched on September 9, 2010, the Vanguard S&P Small-Cap 600 Value Index Fund ETF Shares (VIOV) is a passively managed exchange traded fund designed to provide a broad exposure to the Small Cap Value segment of the US equity market.